Skip to content

Study identifies psychosis as a quantifiable neurological autoimmune disease.

Antibodies defend the body against bacterial, viral, and other invaders. But sometimes the body makes antibodies that attack healthy cells. In these cases, autoimmune disorders develop.  Immune abnormalities in patients with psychosis have been recognized for over a century, but it has been only relatively recently that scientists have identified specific immune mechanisms that seem to directly produce symptoms of psychosis, including hallucinations and delusions.

This ‘immune hypothesis’ is supported by a new study from researchers at The Children’s Hospital at Westmead. They detected antibodies to the dopamine D2 receptor and the N-methyl-D-aspartate (NMDA) glutamate receptor in a subgroup of children experiencing their first episode of psychosis, but no such antibodies in healthy children. Both are key neural signaling proteins that have previously been implicated in psychosis.

In the current study the antibodies detected in children having a first episode of acute psychosis suggest there is a distinct subgroup for whom autoimmunity plays a role in their illness.

For decades psychiatrists have administered drugs that stimulate dopamine D2 receptors or block NMDA receptors. These drugs may briefly produce side effects that resemble symptoms of psychotic disorders, including changes in perception, delusions, and disorganization of thought processes. The current findings suggest that people may develop antibodies that affect the brain in ways that are similar to these psychosis-producing drugs.

The team state that the current study adds fuel to the growing discussions about the importance of antibodies targeting neural proteins and add that it raises many important questions for the field. Therefore, the researchers ask if these antibodies simply function like drugs in the brain or do they ‘attack’ and damage nerve cells in some ways?.  Also, are these antibodies producing symptoms in everyone or do they function as a probe of an underlying, perhaps genetic, vulnerability for psychosis?.

Importantly, work is advancing rapidly in this area. Less than a decade ago, anti-NMDA receptor encephalitis was first identified, a disease characterized by inflammation of the brain that causes acute psychiatric symptoms including psychosis. It is commonly misdiagnosed as schizophrenia or bipolar disorder, but is a form of treatable brain inflammation caused by antibodies that attack the brain’s NMDA receptors.

The team state that the findings suggest that better interventions are possible, providing hope that major disability can be prevented for the subset of children experiencing acute psychosis with antibodies.  These findings also contribute significantly to an emerging acceptance in the field of the involvement of autoimmune antibodies in neurological diseases.

The researchers summise that combined, these investigations are providing a better understanding of the biology of psychiatric and neurological diseases, as well as pointing to novel treatment approaches for children with these debilitating illnesses.

Source:  Elsevier B.V

Credit:  Ian Patrick Coyle, Dr. Barry Ganetzky Laboratory, Michael Gleicher.  UW-Madison Department of Genetics.
Credit: Ian Patrick Coyle, Dr. Barry Ganetzky Laboratory, Michael Gleicher. UW-Madison Department of Genetics.

Healthinnovations View All

Michelle Petersen is the founder of Healthinnovations, having worked in the health and science industry for over 21 years, which includes tenure within the NHS and Oxford University. Healthinnovations is a publication that has reported on, influenced, and researched current and future innovations in health for the past decade.

Michelle has been picked up as an expert writer for Informa publisher’s Clinical Trials community, as well as being listed as a blog source by the world’s leading medical journals, including the acclaimed Nature-Springer journal series.

Healthinnovations is currently indexed by the trusted Altmetric and PlumX metrics systems, respectively, as a blog source for published research globally. Healthinnovations is also featured in the world-renowned BioPortfolio, BioPortfolio.com, the life science, pharmaceutical and healthcare portal.

Most recently the Texas A&M University covered The Top 10 Healthinnovations series on their site with distinguished Professor Stephen Maren calling the inclusion of himself and his team on the list a reflection of “the hard work and dedication of my students and trainees”.

Michelle Petersen’s copy was used in the highly successful marketing campaign for the mega-hit film ‘Jumanji: The Next Level, starring Jack Black, Karen Gilian, Kevin Hart and Dwayne ‘The Rock’ Johnson. Michelle Petersen’s copywriting was part of the film’s coverage by the Republic TV network. Republic TV is the most-watched English language TV channel in India since its inception in 2017.

An avid campaigner in the fight against child sex abuse and trafficking, Michelle is a passionate humanist striving for a better quality of life for all humans by helping to provide traction for new technologies and techniques within healthcare.

4 thoughts on “Study identifies psychosis as a quantifiable neurological autoimmune disease. Leave a comment

  1. Exellent article.
    I would ask if the dopamine D2 receptor and the N-methyl-D-aspartate (NMDA) glutamate receptor antibodies could be related to mother Thyroperoxidase Antibody detection ? Could it be triggered during fetal development ?

  2. I am curious if there is a link available to the study mentioned above? If it is not yet published, is there a projected date of when we can read the original study?

Leave a Reply

Translate »